Medicamen Biotech Ltd logo

Medicamen Biotech Ltd

MEDICAMEQ NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹321 Cr
Volatility
Low Risk
P/E Ratio
44.2
EBITDA
₹20.10 Cr
Return on Equity
7.62%
Debt to Equity
0.15
Book Value
₹203.06
EPS
₹5.81
52W High
₹544
52W Low
₹216.95

Technical Indicators

Key Insights

Strengths

1
  • Stock is trading at 1.14 times its book value

Weaknesses

4
  • The company has delivered a poor sales growth of 5.24% over past five years.
  • Company has a low return on equity of 6.45% over last 3 years.
  • Earnings include an other income of Rs.6.59 Cr.
  • Dividend payout has been low at 10.5% of profits over last 3 years

Growth Rate

Revenue Growth
-7.05% ↘
Net Income Growth
-30.53% ↘
Cash Flow Change
-21.07% ↘
ROE
-32.90% ↘
ROCE
-28.49% ↘
EBITDA Margin (Avg.)
-11.97% ↘

Quarterly Results

  Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Depreciation 1.61.611.681.81.761.771.742.572.170.481.771.811.75
EPS in Rs 2.973.23.492.382.192.441.781.791.981.891.211.631.91
Expenses 28.2630.3833.0936.5138.6138.1836.6236.2934.927.134.4237.1838.41
Interest 0.680.860.960.910.651.870.681.010.730.620.560.840.78
Net Profit 3.764.054.423.012.773.12.262.272.522.41.642.212.59
OPM % 17.17%18.22%18.3%14.44%12.65%15.17%11.72%15.29%15.17%-4.23%10.48%11.96%11.68%
Operating Profit 5.866.777.416.165.596.834.866.556.24-1.14.035.055.08
Other Income 0.630.350.380.550.830.540.580.290.145.220.470.370.53
PBT 4.214.655.1544.013.733.023.263.483.022.172.773.08
Sales 34.1237.1540.542.6744.245.0141.4842.8441.142638.4542.2343.49
Tax % 10.69%13.12%14.37%24.75%31.17%16.62%25.17%30.06%27.59%20.86%24.42%20.22%15.58%

Profit & Loss

  Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Depreciation 2222222366776
Div. Payout % 0%0%0%0%12%10%5%10%8%8%10%13%—
EPS in Rs 0.10.460.484.918.8910.2810.0410.2212.211.8610.467.436.64
Expenses 6873627195105999091113145134137
Interest 4444311223643
Net Profit 00051012121215151399
OPM % 7%6%8%14%15%14%15%18%21%18%16%11%9%
Operating Profit 55612171718202425271713
Other Income 1110242122267
PBT 0016141817171817171311
Sales 73786782112123117110115138172151150
Tax % 44%-267%32%19%27%31%26%25%18%13%21%26%—

Balance Sheet

  Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Borrowings 15211918141211192626302731
CWIP 100001540000000
Equity Capital 9101011121212121213131314
Fixed Assets 22201919252434909292918685
Investments 0000002224888
Other Assets 424941549297100101131180195199258
Other Liabilities 33312329283843395257554848
Reserves 888166375110122136181196205258
Total Assets 65696073118137176192226277294293351
Total Liabilities 65696073118137176192226277294293351

Cash Flow

  Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
CFO/OP 98-6511231-2948888733-2710-7
Financing -43-5-133-42164283-7
Investing -10-1-2-8-15-39-18-8-8-9-2
Operating 5-364-5412135-40-3
Free Cash Flow 4-351-14-11-26-5-4-10-6-5
Net Cash Flow 100020-14-61117-6-11

Ratios

  Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash Conversion Cycle -133222518562623291157188234
Days Payable 209187160165118134160161291232152182
Debtor Days 10212487114126129137165193159102141
Inventory Days 95959510277678528188230237274
ROCE % 13%12%12%24%25%20%15%13%12%11%10%7%
Working Capital Days -32733489116139130146151117186

Shareholding Pattern

40.5%
59.0%
DIIs: 0.44% FIIs: 0.02% Government: 0.05% Promoters: 40.46% Public: 59.02%
  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
DIIs 0.20% 0.20% 0.20% 0.67% ↑0.50.99% ↑0.31.17% ↑0.21.17% 0.87% ↓0.30.69% ↓0.20.64% ↓0.00.59% ↓0.10.44% ↓0.1
FIIs 0.19% 0.16% ↓0.00.22% ↑0.10.22% 0.12% ↓0.10.06% ↓0.10.06% 0.06% 0.12% ↑0.10.00% ↓0.10.05% ↑0.10.02% ↓0.0
Government 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% ↑0.10.06% 0.05% 0.05% 0.05%
Promoters 43.21% 43.21% 43.21% 43.21% 43.21% 42.99% ↓0.242.99% 42.99% 43.16% ↑0.240.46% ↓2.740.46% 40.46%
Public 56.40% 56.44% ↑0.056.38% ↓0.155.90% ↓0.555.69% ↓0.255.78% ↑0.155.79% 56.04% ↑0.355.99% ↓0.058.83% ↑2.858.84% ↑0.059.02% ↑0.2
No. of Shareholders 8,2338,2729,41910,25210,63910,65210,79210,57610,43510,80811,17710,967

Documents

Frequently Asked Questions about Medicamen Biotech Ltd

What does Medicamen Biotech Ltd do?
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
Where is Medicamen Biotech Ltd (MEDICAMEQ) listed?
Medicamen Biotech Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDICAMEQ and BSE: 531146. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Medicamen Biotech Ltd belong to?
Medicamen Biotech Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a market capitalisation of approximately ₹321.30 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Medicamen Biotech Ltd?
The Price-to-Earnings (PE) ratio of Medicamen Biotech Ltd is 44.20. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Medicamen Biotech Ltd?
Over the past 52 weeks, Medicamen Biotech Ltd has traded between a low of ₹216.95 and a high of ₹544. This range helps investors understand the stock's price volatility and recent trading levels.
Does Medicamen Biotech Ltd pay dividends?
Yes, Medicamen Biotech Ltd has a dividend yield of 0.40%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Medicamen Biotech Ltd?
Medicamen Biotech Ltd has a Return on Equity (ROE) of 7.62%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Medicamen Biotech Ltd on Tapetide?
On Tapetide, you can view Medicamen Biotech Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Website medicamen.com
CEO Mr. Rajesh Madan B. Pharma
Employees 376
Listed 2021-10-27
Face Value ₹ 10
Issued Size 1,35,62,815